Converge Bio uses ConvergeAB to improve popular cancer treatment with a single prompt

The findings, which led to a provisional patent filing, suggest Converge Bio improved cetuximab bindings to the receptor, achieving 2x higher affinity using a single AI prompt, strengthening its ability to block cancer-driving signals in colorectal, head, and neck cancers BOSTON and TEL...